Objective:

To determine the prevalence of psychotropic drug-related interventions in patients undergoing metabolic and bariatric surgery (MBS) and to evaluate clinical outcomes related to these interventions.

Approach:

• Study Design: A retrospective study conducted from January 2017 to December 2023, including patients who underwent MBS and were using lithium, tricyclic antidepressants (TCAs), and clozapine.

Key Findings:

• Psychotropic medication management is critical due to pharmacokinetic changes after MBS.
• Patients using lithium, TCAs, and clozapine were monitored for drug adjustments postoperatively.
• Standardized monitoring practices for psychotropic medications post-MBS are lacking.

Interpretation:

The study highlights the need for individualized monitoring of psychotropic medications in patients undergoing MBS due to potential pharmacokinetic alterations.

Limitations:

• Retrospective design may limit the ability to establish causality.
• Lack of standardized monitoring practices may affect the generalizability of findings.

Conclusion:

Individual monitoring of psychotropic drug treatments following MBS is essential to prevent psychiatric destabilization.